Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Common Equity (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Common Equity data on record, last reported at $52.9 million in Q3 2025.

  • For Q3 2025, Common Equity rose 63.11% year-over-year to $52.9 million; the TTM value through Sep 2025 reached $52.9 million, up 63.11%, while the annual FY2024 figure was $43.2 million, 28.72% up from the prior year.
  • Common Equity reached $52.9 million in Q3 2025 per PLX's latest filing, up from $49.9 million in the prior quarter.
  • Across five years, Common Equity topped out at $52.9 million in Q3 2025 and bottomed at -$11.5 million in Q3 2022.
  • Average Common Equity over 5 years is $19.3 million, with a median of $28.6 million recorded in 2024.
  • Peak YoY movement for Common Equity: crashed 5505.63% in 2022, then surged 2854.96% in 2024.
  • A 5-year view of Common Equity shows it stood at -$6.0 million in 2021, then crashed by 76.28% to -$10.6 million in 2022, then soared by 415.5% to $33.6 million in 2023, then rose by 28.72% to $43.2 million in 2024, then rose by 22.44% to $52.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $52.9 million in Q3 2025, $49.9 million in Q2 2025, and $45.2 million in Q1 2025.